Trump announces reforms to accelerate access to psychedelic drug treatments

President signed executive order directing FDA to expedite review of psychedelic drugs including ibogaine Donald Trump on Saturday announced reforms intended to speed up access to medical research and treatment based on psychedelic drugs. The president signed an executive order directing the federal Food and Drug Administration (FDA) to expedite review of drugs such as ibogaine, a drug that US military veteran groups have said can help treat post-traumatic stress disorder .